MediPharm and Aphria made the early, smart decision to pursue the Expanded GMP Licences. They can access markets others are still hoping will generate future revenues.
Both companies are first movers beyond Canada, and stand to generate significant revenues beyond Canadian shores.
Aphria's CC Pharma in Germany contributed over $90M last Q. That bodes well for MediPharm. They are looking beyond just Germany's nearly 2.3x population vs Canada. MediPharm is pursues deals worldwide.
The EU is nearly 13x the size of Canada's population.
But in addition, the GMP Licences are going to attract Central and South American deals as Brazil and Peru evidenced.
Incredibly, my months ago thoughts that the PPS might drop to 50¢ is a lot closer today than after they announced the Denmark deal.
I bought on Tuesday, and will be buying again soon. IMO, the drop gets crazier with every announced deal.
News 
Market Data 
Discover 
